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Introduction 
Machine learning algorithms are an application of artificial intelligence designed to 
automatically detect patterns in data without being explicitly programmed. They 
promise to change the way we detect and treat disease and will likely have a major 
impact on clinical decision making. The long term success of these powerful new 
methods hinges on the ability of both patients and doctors to understand and explain 
their predictions, especially in complicated cases with major healthcare consequences. 
This will promote greater trust in computational techniques and ensure informed 
consent to algorithmically designed treatment plans. 
Unfortunately, many popular machine learning algorithms are essentially black 
boxes—oracular inference engines that render verdicts without any accompanying 
justification. This problem has become especially pressing with passage of the European 
Union’s latest General Data Protection Regulation (GDPR), which some scholars argue 
provides citizens with a “right to explanation.” Now, any institution engaged in 
algorithmic decision making is legally required to justify those decisions to any person 
whose data they hold on request, a challenge that most are ill equipped to meet. We urge 
clinicians to link with patients, data scientists, and policy makers to ensure the 
successful clinical implementation of machine learning. We outline important goals and 
limitations that we hope will inform future research. 
Predictions versus explanations 
Predictions tell us that x is true; explanations tell us why x is true. The past decade has 
seen enormous advances in our ability to predict complex phenomena using 
computational techniques. Explanatory breakthroughs, on the other hand, have been 
few and far between. 
Machine learning algorithms have already shown expert diagnostic performance 
based on imaging data for conditions including diabetic retinopathy,1 skin cancer,2 and 
pneumonia.3 Precision medicine seeks to go further, modelling molecular data to 
classify patients according to endotype,4 defining disease mechanism and ontologies.5 
With the integration of electronic health records and wearable medical sensors, machine 
learning may usher in a new era of real time diagnostic updates, enabling earlier, more 
targeted interventions.6 
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Machine learning techniques are already emerging in clinical practice.7 Microsoft’s 
InnerEye offers a graphical user interface to algorithms that help radiologists diagnose 
cancerous tumours and plan precise surgical interventions.8 DeepMind Health recently 
partnered with Moorfields Eye Hospital to develop models for diagnosing common 
retinal pathologies based on optical coherence tomography scans.9 IBM’s Watson for 
Oncology seeks to provide personalised cancer care based on health records,10 although 
the project has run into numerous procurement problems, cost overruns, and delays.11 
One frequently cited obstacle to machine learning’s wider clinical adoption is a lack 
of understanding among patients and doctors about how predictions are made.12 This is 
especially true of some top performing algorithms, like the deep neural networks used in 
image recognition software. These models may reliably discriminate between malignant 
and benign tumours, but they offer no explanation for their judgments. Of course, 
clinicians are not always able to perfectly account for their own inferences, which may 
be based more on experience and intuition than explicit medical criteria.13 Moreover, 
doctors do not optimally integrate all available evidence, and cognitive biases can be 
deeply entrenched.14 Still, many think that, as a new technology, the burden of proof is 
on machine learning to account for its predictions. If doctors do not understand why the 
algorithm made a diagnosis, then why should patients trust the recommended course of 
treatment? Is informed consent even possible without some grasp of how the model 
reached its conclusion? 
Not all algorithms are black boxes. Some sophisticated models, such as those based 
on regularised linear regression, provide a modest number of informative parameters.15 
Yet, although restricting the use of clinical machine learning to more intelligible 
algorithms is tempting, it would be a mistake. No single technique is optimal for all 
cases—a result known as the “no free lunch theorem” in computer science16—which 
means that any attempt to shoehorn all datasets into a particular family of statistical 
models is guaranteed to fail. 
The opportunity costs of not using our best available tools for disease detection and 
treatment are substantial—12 million people a year receive misdiagnoses in the United 
States, with about six million facing potential harm as a result.17 Nearly one third of all 
preventable deaths in the United Kingdom are attributable to misdiagnosis.18 The 
benefits of early disease detection are well known. 
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Yet clinicians are right to be sceptical of inscrutable models. Especially worrisome is 
the risk of overfitting to an unrepresentative sample. In one famous example, an 
algorithm designed to predict probability of death among hospital patients with 
pneumonia systematically classified asthmatics as low risk.19 The correlation was 
spurious—patients with asthmatic pneumonia were sent directly to the intensive care 
unit, where they received continuous treatment that improved their prognosis so 
substantially that they seemed to have better than average chances of survival. Mistakes 
like this show the potential dangers of naively accepting the outputs of a black box 
model. They also raise important questions about liability in cases of algorithmic error. 
Who is ultimately responsible for a computational misdiagnosis? Clinicians? Data 
scientists? Policy makers have tackled similar questions in other contexts and come to 
no clear consensus.20 
Right to explanation? 
The GDPR has emphasised “explainability” as a top priority in machine learning 
research, provoking a global debate over the right to explanation in cases where 
individuals are subject to automated decisions. Whether or not this purported right is 
enshrined in the GDPR—a point of contention among legal scholars21—there are 
compelling reasons to endorse it in medical contexts. This will require a total 
reorientation of priorities for data scientists, who are more used to optimising for 
accuracy than for intelligibility. 
Before we can design new methods to tackle this challenge, we must agree on what 
constitutes a satisfactory explanation. Do we want to understand all the patterns the 
machine has learnt (model-centric explanations)? Or just those that are relevant to the 
patient (subject-centric explanations)?22 The former aims to provide global 
understanding about the relative importance of all variables and how they interact to 
make predictions, which may shed new light on disease mechanisms; the latter provides 
local understanding about why this particular input led to that particular output, which 
could be relevant for individual patient prognosis. 
Clinicians sceptical of machine learning tend to focus on the lack of clear model-
centric explanations.19 Deep neural networks, for example, routinely contain millions of 
parameters, assigning weights and biases to thousands of nodes in an architecture so 
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complex that no human could plausibly be expected to grasp the whole model’s internal 
mechanics. But if a computer truly outperforms doctors in making diagnoses, then we 
would like to know why. Understanding the biological patterns or processes it has 
uncovered could advance our knowledge and help build the medical community’s trust 
in such systems. 
Of course, patients are the most critical stakeholders in clinical machine learning. 
Enabling them to appreciate their algorithmically determined diagnosis and treatment 
options is crucial—but also complicated, especially when inputs include high 
dimensional genomics or imaging data. Researchers in the nascent field of interpretable 
machine learning have implemented methods for generating model-agnostic local 
explanations.23, 24 These approaches are promising, but more work is needed to extend 
them to clinical settings and support them with the appropriate medical ethics 
framework. 
The path forward 
Current proposals struggle to meet two important criteria for the clinical application of 
machine learning: scalability and customisability. With biological datasets often 
containing millions of variables per sample, the computational complexity of 
explanatory methods for molecular models must be constrained. This entails an 
inherent trade-off between completeness and simplicity. Ideally, users could specify a 
level of explanatory granularity that best suits their needs. Some may prefer diagnoses 
to be explained in terms of basic, familiar biological concepts; others may opt for a more 
detailed account in terms of molecular mechanisms. 
Important unanswered questions remain about how best to measure the utility of a 
given explanation. Some authors have attempted to formalise the problem in a 
computable fashion,25 whereas others advocate a more empirical approach driven by 
experimental psychology.26 Both methods have their merits and drawbacks, but building 
a research programme around either will be difficult without first establishing a broad 
consensus. 
Some caution with regard to transparency is advisable. A fully open source approach 
may enable misuse of the algorithm for harmful purposes outside the clinical context. 
This is particularly problematic when a diagnosis is based on easily accessible data, such 
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as facial images or movement patterns.27 Scrutiny of machine learning is important but 
should not expose people to disproportionate risks or privacy violations, especially when 
there is no immediate benefit to diagnosis, as is the case with currently untreatable 
conditions. 
We are only just beginning to realise machine learning’s potential for medicine, and 
although it remains exploratory the benefits should not be ignored. Patients, clinicians, 
and data scientists must collaborate to develop new methods for extracting model-
centric and patient-centric explanations that can provide global and local 
understanding. Bringing algorithms into the clinic can advance knowledge and improve 
care, but only if we are prepared to devote sufficient resources to illuminating the black 
box for doctors and patients alike. 
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